Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine
NCT00482027
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
80
Enrollment
NETWORK
Sponsor class
Conditions
HIV Infection
Interventions
BIOLOGICAL:
tgAAC09
Sponsor
International AIDS Vaccine Initiative
Collaborators
[object Object]
[object Object]
[object Object]